Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effects of Vortioxetine on Cognition and Fatigue in Patients with Multiple Sclerosis and Depression: A Case Series Study

Author(s): Anna Gil-Sanchez*, Marc Canudes, Petya Valcheva, Lara Nogueras, Cristina González-Mingot, José Vicente Hervás, Silvia Peralta, Maria Solana and Luis Brieva

Volume 23, Issue 3, 2024

Published on: 27 April, 2023

Page: [395 - 401] Pages: 7

DOI: 10.2174/1871527322666230321093133

Price: $65

Abstract

Introduction: Vortioxetine is a multimodal antidepressant drug that has been reported to have a positive impact on cognition, social function, and fatigue. Nevertheless, it has not been widely studied. Our objective was to explore the effects of vortioxetine on these and other parameters in patients with multiple sclerosis (MS) and depression.

Patients and Methodology: This observational case series study included patients with MS and depression who received treatment with vortioxetine for at least 6 months. The patient history of depression and depressive symptoms was assessed. A neuropsychiatric evaluation was carried out using different scales, both before and after treatment.

Results: Of the 25 patients who enrolled in the study, 17 completed the treatment. Significant improvements were observed in health status (EQ-5D; p = 0.002), mood (Beck’s Depression Inventory, BDI-II; p = 0.006), anxiety (State-Trait Anxiety Inventory, STAI-State; p = 0.021, and STAI-Trait; p = 0.011), and in the general health test (Short Form Health Survey, SF-36) for the vitality (p = 0.028) and mental health (p = 0.025) domains of the patients who completed the treatment. However, no statistically significant differences were observed in the cognitive tests related to attention, information processing speed, or fatigue.

Conclusion: In this population, vortioxetine treatment was effective in reducing the symptoms of depression and improving anxiety, vitality, and mental health. In contrast, it did not produce any improvement in cognition or fatigue but an increase in sample size would be necessary to confirm these results.

« Previous Next »
Graphical Abstract

[1]
Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015; 5(9): e00362.
[http://dx.doi.org/10.1002/brb3.362] [PMID: 26445701]
[2]
Fernandez O, Fernandez VE, Guerrero M. Esclerosis múltiple. Spain: Momento Médico Iberoamericana 2010.
[3]
Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci 2017; 372: 331-41.
[http://dx.doi.org/10.1016/j.jns.2016.11.067] [PMID: 28017241]
[4]
Smith SJ, Young CA. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil 2000; 14(1): 50-4.
[http://dx.doi.org/10.1191/026921500676724210] [PMID: 10688344]
[5]
Solaro C, Gamberini G, Masuccio FG. Depression in multiple sclerosis: Epidemiology, aetiology, diagnosis and treatment. CNS Drugs 2018; 32(2): 117-33.
[http://dx.doi.org/10.1007/s40263-018-0489-5] [PMID: 29417493]
[6]
Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36(4): 578-84.
[http://dx.doi.org/10.1345/aph.1A254] [PMID: 11918502]
[7]
Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003; 25(8): 2289-304.
[http://dx.doi.org/10.1016/S0149-2918(03)80220-5] [PMID: 14512135]
[8]
Trindade E, Menon D, Topfer L-A, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159(10): 1245-52.
[PMID: 9861221]
[9]
Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017; 17(1): 1-28.
[PMID: 28049496]
[10]
Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: A brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Relat Disord 2017; 18: 177-80.
[http://dx.doi.org/10.1016/j.msard.2017.10.004] [PMID: 29141805]
[11]
Solaro C, Bergamaschi R, Rezzani C, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol 2013; 36(4): 114-6.
[http://dx.doi.org/10.1097/WNF.0b013e3182996400] [PMID: 23783007]
[12]
Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol Ther 2015; 145: 43-57.
[http://dx.doi.org/10.1016/j.pharmthera.2014.07.001] [PMID: 25016186]
[13]
Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014; 19(2): 121-33.
[http://dx.doi.org/10.1017/S1092852913000540] [PMID: 23903233]
[14]
Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015; 14(8): 1291-304.
[http://dx.doi.org/10.1517/14740338.2015.1046836] [PMID: 26022537]
[15]
McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: A meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol 2016; 19(10): pyw055.
[http://dx.doi.org/10.1093/ijnp/pyw055] [PMID: 27312740]
[16]
Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. J Affect Disord 2018; 227: 787-94.
[http://dx.doi.org/10.1016/j.jad.2017.11.081] [PMID: 29689693]
[17]
Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019; 15: 1249-58.
[http://dx.doi.org/10.2147/NDT.S199746] [PMID: 31190831]
[18]
McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014; 17(10): 1557-67.
[http://dx.doi.org/10.1017/S1461145714000546] [PMID: 24787143]
[19]
Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019; 24(6): 616-27.
[http://dx.doi.org/10.1017/S1092852919000786] [PMID: 30802419]
[20]
Cumbo E, Cumbo S, Torregrossa S, Migliore D. Treatment effects of vortioxetine on cognitive functions in mild Alzheimer’S disease patients with depressive symptoms: a 12 month, open-label, observational study. J Prev Alzheimers Dis 2019; 6(3): 192-7.
[PMID: 31062834]
[21]
Cao B, Park C, Subramaniapillai M, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry 2019; 10: 17.
[http://dx.doi.org/10.3389/fpsyt.2019.00017] [PMID: 30766492]
[22]
Medina J, García de León M. Efectos secundarios de los antidepresivos. Vigilia-Sueno 2004; 16(1): 48-57.
[23]
Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. J Affect Disord 2019; 250: 114-22.
[http://dx.doi.org/10.1016/j.jad.2019.03.040] [PMID: 30852363]
[24]
Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2015; 40(8): 2025-37.
[http://dx.doi.org/10.1038/npp.2015.52] [PMID: 25687662]
[25]
Nierenberg AA, Loft H, Olsen CK. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. J Affect Disord 2019; 250: 35-42.
[http://dx.doi.org/10.1016/j.jad.2019.02.006] [PMID: 30826492]
[26]
Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27(4): 215-23.
[http://dx.doi.org/10.1097/YIC.0b013e3283542457] [PMID: 22572889]
[27]
Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, et al. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep 2017; 69(4): 595-601.
[http://dx.doi.org/ 10.1016/j.pharep.2017.01.030] [PMID: 28499187]
[28]
Diagnostic and statistical manual of mental disorders. (5th ed.), Arlington, VA: American Psychiatric Association 2013.
[29]
Rabin R, Charro FEQ-SD. a measure of health status from the EuroQol Group. Ann Med 2001; 33(5): 337-43.
[http://dx.doi.org/10.3109/07853890109002087] [PMID: 11491192]
[30]
Smith A. The Symbol Digit Modalities Test: A neutopsychologic test for economic screening of learning and other cerebral disorders.In: Learning Disorders. Seattle: Special Child Publications 1968; pp. 83-91.
[31]
Benedict RHB, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 2017; 23(5): 721-33.
[http://dx.doi.org/10.1177/1352458517690821] [PMID: 28206827]
[32]
Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306(6890): 1437-40.
[http://dx.doi.org/10.1136/bmj.306.6890.1437] [PMID: 8518639]
[33]
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46(10): 1121-3.
[http://dx.doi.org/10.1001/archneur.1989.00520460115022] [PMID: 2803071]
[34]
Beck A, Steer R, Brown G. Manual BDI-II Inventario de Depresión de Beck-II (Adaptación española: Sanz, J, y Vázquez, C). Madrid: Pearson 2011.
[35]
Spielberger CD, Gorsuch RL, Lushene RE, Cubero NS. STAI: State-Trait Anxiety Questionnaire: TEA editions Madrid. 1999.
[36]
Statistics I. IBM Corp Released 2013 IBM SPSS Statistics for Windows, Version 220. Armonk, NY: IBM Corp. 2013.
[37]
Klinkenberg I, Sambeth A, Blokland A. Acetylcholine and attention. Behav Brain Res 2011; 221(2): 430-42.
[http://dx.doi.org/10.1016/j.bbr.2010.11.033] [PMID: 21108972]
[38]
Manjaly ZM, Harrison NA, Critchley HD, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry 2019; 90(6): 642-51.
[http://dx.doi.org/10.1136/jnnp-2018-320050] [PMID: 30683707]
[39]
Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30(3): 242-52.
[http://dx.doi.org/10.1177/0269881116628440] [PMID: 26864543]
[40]
Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults: A randomized, controlled trial. J Sex Med 2019; 16(10): 1638-49.
[http://dx.doi.org/10.1016/j.jsxm.2019.06.018] [PMID: 31405765]
[41]
Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: A pooled analysis. CNS Spectr 2016; 21(5): 367-78.
[http://dx.doi.org/10.1017/S1092852915000553] [PMID: 26575433]
[42]
Liguori C, Ferini-Strambi L, Izzi F, et al. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: A retrospective questionnaire analysis. Br J Clin Pharmacol 2019; 85(1): 240-4.
[http://dx.doi.org/10.1111/bcp.13772] [PMID: 30328132]
[43]
Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 1991; 41(5): 685-91.
[http://dx.doi.org/10.1212/WNL.41.5.685] [PMID: 2027484]
[44]
Dineen RA, Vilisaar J, Hlinka J, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009; 132(1): 239-49.
[http://dx.doi.org/10.1093/brain/awn275] [PMID: 18953055]
[45]
Talebi M, Majdi A, Nasiri E, Naseri A, Sadigh-Eteghad S. The correlation between circulating inflammatory, oxidative stress, and neurotrophic factors level with the cognitive outcomes in multiple sclerosis patients. Neurol Sci 2021; 42(6): 2291-300.
[http://dx.doi.org/10.1007/s10072-020-04807-6] [PMID: 33033896]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy